Countervail Corporation


Countervail Corporation presents significant results of orally dosed AverTox (galantamine) for improved survival from exposure to lethal levels of soman at the CounterACT Symposium held at the New York Academy of Sciences.


Data collected from an SBIR grant awarded by NIH was presented at the annual CounterACT meeting held at the New York Academy of Sciences in June 2015. In summary, the data supported the use of AverTox® (galantamine), given orally as a pre-treatment for lethal soman exposure, as providing significant improvement in survival over the use of conventional care drugs alone.